Early toxicity and dosimetry compliance of hypofractionated vs. conventional fractionated comprehensive regional nodes irradiation in breast cancer (HARVEST)
In brief
Short-course breast radiotherapy halves moderate dermatitis, with similar overall acute toxicity
In this randomized trial of 801 patients receiving breast and regional-node radiation, grade 2 or worse dermatitis was about half as common with the 15-treatment schedule as with the 25-treatment schedule. Overall moderate or worse acute toxicity and cosmetic outcomes were similar; longer follow-up is still needed to establish long-term safety and cancer control.
- Journal
- International journal of radiation oncology, biology, physics (Q1)
- Published
- 12 November 2026
- Study design
- Non-randomized / quasi-experimental trial
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Feifei Xu, Xiaobo Huang, Gang Cai, Dan Ou, Yutian Zhao, Qiwei Zhu, et al.
- PMID
- 43020386
- DOI
- 10.1016/j.ijrobp.2026.10.050
Why clinicians should know about it
- Picked for Radiation Oncology (paper of the day, 13 November 2026): Phase III randomized comparison of breast nodal radiation fractionation
- Picked for Radiology, Radiation Oncology, Nuclear Medicine, Medical Physics and Imaging (paper of the day, 13 November 2026): Hypofractionated vs conventional RNI breast trial
Abstract
PURPOSE: The HARVEST trial is a phase III randomized controlled trial comparing hypofractionated with conventional fractionated radiotherapy (HF-RT vs. CF-RT) with regional nodal irradiation (RNI, including internal mammary nodes [IMNs]) in breast cancer patients. In this study, we report the early toxicity profile, cosmetic outcomes and dosimetric quality assurance results. METHODS AND ANALYSIS: Enrolled patients were randomized into the HF-RT group (40.05 Gy/15 Fx) or CF-RT group (50 Gy/25 Fx). Acute toxicity was assessed with the Common Terminology Criteria for Adverse Events (CTCAE) V.3.0 scale. Cosmetic outcome was assessed using the Harvard scale. RESULTS: There were 400 and 401 patients enrolled in HF-RT and CF-RT group from eight centers in China, respectively. Protocol compliances exceeded 90% for most targets coverage and organs at risk constraint parameters in both groups, although IMN coverage was less complete than that of the chest wall/whole breast and supra/infraclavicular nodes. There was no significant difference of grade ≥ 2 acute toxicities between groups (RR, 0.79; 95% CI, 0.52-1.22; p=0.29). Dermatitis was the most common acute toxicity, with a significantly lower rate of grade ≥ 2 events in the HF-RT group than in the CF-RT group (RR, 0.48; 95% CI, 0.25-0.92; p=0.03). No significant differences were observed in other acute toxicities (including fatigue, pneumonitis, breast pain, dysphagia and breast edema) or in the proportion of good or excellent cosmesis among breast-conserving patients between groups. CONCLUSION: We found comparable acute toxicity and cosmesis results in HF-RT with RNI compared to CF-RT. The technical protocol was highly feasible with good protocol compliance. Additional follow-up is needed to assess the long-term efficacy and safety.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.